ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $3.01B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.17M
Average 7.07M
ADMA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
ADMA Biologics, Inc.NASDAQ: ADMA
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows, but more slowly than its trailing trend
Q2 FY2026 revenue of $124.4M rose 2.0% year over year, behind the +8.0% change in trailing-twelve-month revenue. Sequentially, it rose 8.6% from the prior quarter. Over 3 fiscal years it compounded at +49.0% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $534.79M (+4.8%) for the fiscal year ending Dec 2026, a slowdown from the +19.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $124.4M+8.6% QoQ
- Last fiscal yearDec 2025
- $510.17M+19.6% YoY
- LTMJun 2026
- $512.28M+8.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.0% | +2.9% | +0.9 pp |
| 1 year | +19.6% | +4.8% | -14.8 pp |
| 3-year CAGR | +49.0% | +11.0% | -38.0 pp |
| 5-year CAGR | +11.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 510.17M USD
- Year-over-year change
- +19.6%
- 4-year CAGR
- +58.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 510.17M | +19.6% |
| FY2024 | 2024-12-31 | 426.45M | +65.2% |
| FY2023 | 2023-12-31 | 258.22M | +67.6% |
| FY2022 | 2022-12-31 | 154.08M | +90.4% |
| FY2021 | 2021-12-31 | 80.94M | — |
Revenue vs competitors
How ADMA compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +8.0% is the 3rd highest of 4, against a peer median of +52.3%.
- Over three fiscal years its annual growth of +49.0% compares with a peer median of -11.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | €7.43B EUR | -0.2% | +6.0% | |
| LTM Jun 2026 | $512.28M USD | +8.0% | +49.0% | |
| LTM Mar 2026 | $191.45M USD | +2889.9% | -28.8% | |
| LTM Mar 2026 | $55.87M USD | +52.3% | — | |
| Peer median (excluding ADMA) | — | +52.3% | -11.4% | |
Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 80.94M | 154.08M | 258.22M | 426.45M | 510.17M |
| Cost of Revenue | 79.77M | 118.82M | 169.27M | 206.9M | 217.41M |
| Gross Profit | 1.17M | 35.27M | 88.94M | 219.55M | 292.77M |
| Gross Margin | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% |
| Research & Development | 3.65M | 3.61M | 3.3M | 1.81M | 4.76M |
| Selling, General & Admin | 42.9M | 52.46M | 59.02M | 74.12M | 91.58M |
| Operating Expenses | 59.55M | 74.63M | 67.31M | 80.57M | 101.32M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| EBITDA | (53.1M) | (39.51M) | 5.12M | 147.69M | 197.86M |
| EBITDA Margin | -65.6% | -25.6% | 2.0% | 34.6% | 38.8% |
| Operating Income | (58.37M) | (39.37M) | 21.63M | 138.98M | 191.44M |
| Operating Margin | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% |
| Interest Income | 34.53K | 44.83K | 1.62M | 2.1M | 1.87M |
| Interest Expense | 13.06M | 19.28M | 25.03M | 13.93M | 7.11M |
| Other Income / Expenses | (13.27M) | (26.54M) | (49.87M) | (13.27M) | (8.79M) |
| Income Before Tax | (71.65M) | (65.9M) | (28.24M) | 125.71M | 182.66M |
| Pre-Tax Margin | -88.5% | -42.8% | -10.9% | 29.5% | 35.8% |
| Income Tax Expense | 0 | 0 | 0 | (71.96M) | 35.73M |
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Net Margin | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% |
| EPS (Basic) | (0.61) | (0.43) | (0.13) | 0.85 | 0.62 |
| EPS (Diluted) | (0.61) | (0.43) | (0.13) | 0.81 | 0.60 |
| Weighted Avg Shares | 139.58M | 197.87M | 223.98M | 233.08M | 238.3M |
| Weighted Avg Shares (Diluted) | 139.58M | 197.87M | 223.98M | 243.34M | 244.9M |
ADMA Biologics, Inc.
NASDAQ:ADMA
Intrinsic Alpha fair value
Locked
Current Price
$13.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.